PR Newswire
Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40
📈
AI Sentiment
Highly Positive
8/10
- Home
- JNJ
as of 12-03-2025 3:55pm EST
$205.64
+$0.22
+0.11%
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Chart Type:
Time Range:
| Founded: | 1886 | Country: | United States |
| Employees: | N/A | City: | NEW BRUNSWICK |
| Market Cap: | 449.6B | IPO Year: | 1944 |
| Target Price: | $198.00 | AVG Volume (30 days): | 9.0M |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 10.35 | EPS Growth: | 71.26 |
| 52 Week Low/High: | $140.68 - $207.81 | Next Earning Date: | 01-21-2026 |
| Revenue: | $92,149,000,000 | Revenue Growth: | 5.08% |
| Revenue Growth (this year): | 6.6% | Revenue Growth (next year): | 5.28% |
AI-Powered JNJ Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 71.97%
71.97%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Johnson & Johnson (JNJ)
MORIKIS JOHN G
Buy
Director
JNJ Nov 26, 2025
Avg Cost/Share
$206.15
Shares
1,250
Total Value
$257,687.50
Owned After
1,848.51
SEC Form 4
REED JOHN C
Sell
EVP, Innovative Medicine, R&D
JNJ Oct 17, 2025
Avg Cost/Share
$192.71
Shares
21,721
Total Value
$4,185,793.09
Owned After
10,658
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| MORIKIS JOHN G | JNJ | Director | Nov 26, 2025 | Buy | $206.15 | 1,250 | $257,687.50 | 1,848.51 | |
| REED JOHN C | JNJ | EVP, Innovative Medicine, R&D | Oct 17, 2025 | Sell | $192.71 | 21,721 | $4,185,793.09 | 10,658 |
Latest Johnson & Johnson News
JNJ Breaking Stock News: Dive into JNJ Ticker-Specific Updates for Smart Investing
Insider Monkey
Johnson & Johnson’s (JNJ) Multiple Myeloma Breakthrough Drives Buy Rating From Guggenheim
📈
AI Sentiment
Highly Positive
8/10
GlobeNewswire
Medication Adherence Research Report 2025: Market to Reach $3.63 Billion by 2030, Driven by Rising Chronic Disease Burden, Aging Populations, and Growing Adoption of Digital Health Tools
📈
AI Sentiment
Highly Positive
8/10
Zacks
JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis
📈
AI Sentiment
Highly Positive
8/10
PR Newswire
LifeStyles Healthcare Appoints Peter Luther to Board of Directors
📈
AI Sentiment
Highly Positive
8/10
Barrons.com
Exxon and 15 More ‘Quality’ Stocks to Own for a Volatile Market
➖
AI Sentiment
Neutral
5/10
24/7 Wall St.
Time to Shore Up Your Personal Portfolio With These 3 Bullet-Proof Blue-Chip Stocks
📊
AI Sentiment
Positive
6/10
Compare JNJ vs Leading Stocks
See how JNJ stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "JNJ Johnson & Johnson - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.